Sanofi (SNY) Receives Daily Media Sentiment Score of 0.04
News coverage about Sanofi (NYSE:SNY) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sanofi earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.9939422967185 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak (finance.yahoo.com)
- Eroding Analytics Drop Sanofi (SNY) to Buy (investorplace.com)
- Earnings Reaction History: Sanofi-Aventis, 33.3% Follow-Through Indicator, 1.7% Sensitive – Nasdaq (nasdaq.com)
- What Analysts Recommend for Sanofi in 3Q17 – Market Realist (marketrealist.com)
- [$$] Diabetes Division Weighs on Sanofi’s 3Q Profits (finance.yahoo.com)
Sanofi (SNY) opened at $46.08 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The stock has a market cap of $115,333.78, a P/E ratio of 14.43, a P/E/G ratio of 2.03 and a beta of 0.88. Sanofi has a 1-year low of $38.45 and a 1-year high of $50.65.
A number of analysts have recently issued reports on SNY shares. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. BidaskClub downgraded shares of Sanofi from a “hold” rating to a “sell” rating in a report on Monday, July 24th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price target (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, Argus reaffirmed a “buy” rating and set a $55.00 price target on shares of Sanofi in a report on Friday, September 1st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. Sanofi currently has a consensus rating of “Hold” and a consensus target price of $53.50.
WARNING: “Sanofi (SNY) Receives Daily Media Sentiment Score of 0.04” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/sanofi-sny-receives-daily-media-sentiment-score-of-0-04/1684656.html.
In other Sanofi news, major shareholder Sanofi acquired 105,820 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average price of $482.04 per share, with a total value of $51,009,472.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.00% of the company’s stock.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.